Morning Market Movers

shares surged 73.11% to $8.24 ahead of January 5 conference call to discuss final results of Phase 2a trial of NurOwn in ALS.

shares gained 15.48% to $18.20 after the company reported Chairman's preliminary non-binding 'go-private' offer at $20 per ADS. The company also named Yunfan Zhang as COO.

shares rose 7% to $17.16. Regulus Therapeutics shares have jumped 117.94% over the past 52 weeks, while the S&P 500 index has gained 12.39% in the same period.

shares rose 4.63% to $14.69 after tumbling 22.60% on Wednesday.

shares gained 3.49% to $59.68. Credit Suisse reiterated an Outperform rating on Kite Pharma and raised the price target from $34.00 to $71.00.

shares gained 3% to $7.75 after the company reported December same-store sales. Total drugstore sales for the four-week period increased 4.9 percent to $2.212 billion compared to $2.109 billion for the same period last year.

shares climbed 2.64% to $35.36. Stephens & Co. upgraded Fidelity National from Equal-weight to Overweight and raised the price target from $31.00 to $43.00.

shares rose 2.59% to $68.80. Raymond James upgraded Quest Diagnostics from Underperform to Market Perform.